Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may ... sleep disturbances and non-infectious gastroenteritis, which is inflammation of the digestive tract which ...